Insight journal - Dealtalk

AstraZeneca is eyeing Forest Laboratories for acquisition

Posted on 05 December 2013

Tags: , , ,

AstraZeneca (AZ) is considering a acquisition bid for Forest Laboratories of the US, according to a Financial Times report which cites people close to two companies.

The rumour comes shortly after recently appointed Forest chief executive Brenton Saunders announced a major shake-up of the company's operations, including a cost-cutting programme aimed at trimming $500m off its cost base and a $400m share buyback.

The FT suggests AZ financial advisers recently met the senior management at Forest to discuss a cash offer for the company, which is valued at around $15bn, but that the negotiations are still in very preliminary stages.

At that valuation, any bid for Forest could rival the $15.6bn AZ paid for Medimmune five years ago to boost its biologics pipeline, a deal which some have suggested was priced too high.

One of the draws for AZ is that Forest's product pipeline is pretty closely aligned with its own R&D priorities, with a particular focus on treatments for central nervous system (CNS) disorders as well as cardiovascular and respiratory medicine and infectious diseases.

After several pipeline setbacks, AZ has signed a string of acquisition and licensing deals under CEO Pascal Soriot, who took over the reins of the pharma giant last year with a pledge to streamline and reform the business.

Last month the company agreed to pay $440m to buy antibody-drug conjugate (ADC) specialist Spirogen, while in August it bought cancer company Amplimmune in a deal valued at up to $500m. Earlier this year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as US biotechs AlphaCore Pharma and Omthera Pharmaceuticals.

Analysts suggested that the timing of Forest's restructuring drive - in particular with share buyback - may be a defensive measure to make sure it secures a premium price in any buy-out of the business.

View the article at News Release

 

Related

Report: Partnering Deals and Alliances with Big Pharma                              

Report: Partnering Deals and Alliances with Big Biotech

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif